Liposomal cytarabine for treatment of myeloid central nervous system relapse in chronic myeloid leukaemia occurring during imatinib therapy

European Journal of Clinical Investigation

Volumn 37, Issue 10, 2007, Pages 808-813

  Aichberger, K J ^a   Herndlhofer, S ^a   Agis, H ^a   Sperr, W R ^a   Esterbauer, H ^a   Rabitsch, W ^a   Knobl P ^a   Haas, O A ^b   Thalhammer, R ^a   Schwarzinger, I ^a   Sillaber, C ^a   Jager U ^a   Valent, P ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b CHILDREN'S CANCER RESEARCH INSTITUTE   (Austria)

Author keywords

CML; CNS relapse; Dasatinib; Imatinib; Liposomal cytarabine

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; CYTARABINE; DASATINIB; IMATINIB; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

ADULT; AGED; ANEMIA; ARTICLE; CANCER CELL; CANCER RADIOTHERAPY; CANCER RELAPSE; CASE REPORT; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CYTOGENETICS; DRUG DOSE INCREASE; FEMALE; HUMAN; IMMUNOPHENOTYPING; MALE; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUBERCULOSIS;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CENTRAL NERVOUS SYSTEM NEOPLASMS; CYTARABINE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LIPOSOMES; MALE; MIDDLE AGED; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; THIAZOLES; TREATMENT OUTCOME;

EID: 34748923568     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2007.01859.x     Document Type: Article

References (39)

1. Rowley JD. A new consistent abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and giemsa staining. Nature 1973 243 : 290 3.
2. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukaemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990 247 : 824 30.
3. Faderl S, Tapaz M, Estrov Z. The biology of chronic myelogenous leukemia. N Eng J Med 1999 341 : 164 72.
4. Vardiman JW, Pierre R, Thiele J, Imbert M, Brunning RD, Flandrin G. Chronic myelogenous leukaemia. In : Jaffe ES, (Ed). Tumours of Haematopoietic and Lymphoid Tissues, Pathology & Genetics, World Health Organization Classification of Tumors, 1st edn. Lyon : IRAC Press 2001, pp. 20 6.
5. Sattler M, Griffin JD. Molecular mechanisms of transformation by the BCR-ABL oncogene. Semin Hematol 2003 40 : 4 10.
6. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmocol Exp Ther 2000 295 : 139 45.
7. Druker BJ. Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML. Oncogene 2002 21 : 8541 6.
8. Capdeville R, Buchdunger E, Zimmermann J, Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 2002 1 : 493 502.
9. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003 348 : 994 1004.
10. Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003 349 : 1423 32.
11. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006 355 : 2408 17.
12. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN et al. Clinical resistance to STI-571 cancer therapy caused by BCR/ABL gene mutation or amplification. Science 2001 293 : 876 80.
13. Weisberg E, Griffin JD. Resistance to imatinib (Glivec): update on clinical mechanisms. Drug Resist Updat 2003 6 : 231 8.
14. Hochhaus A, Kreil S, Corbin AS, La Rosee P, Muller MC, Lahaye T et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002 16 : 2190 6.
15. Thomas J, Wang L, Clark RE, Pirmohamed M. Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004 104 : 3739 45.
16. Jiang X, Zhao Y, Smith C, Gasparetto M, Saw KM, Turhan A et al. Chronic myeloid leukemia stem cells possess unique properties that predict intrinsic and acquired resistance to imatinib mesylate. Blood 2006 108 : 226a.
17. Barnes DJ, Melo JV. Primitive, quiescent and difficult to kill: the role of non-proliferating stem cells in chronic myeloid leukemia. Cell Cycle 2006 5 : 2862 6.
18. Petzer AL, Gunsilius E, Hayes M, Stockhammer G, Duba HC, Schneller F et al. Low concentrations of STI571 in the cerebrospinal fluid: a case report. Br J Haematol 2002 117 : 623 5.
19. Takayama N, Sato N, O'Brien SG, Ikeda Y, Okamoto S. Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid. Br J Haematol 2002 119 : 106 8.
20. Abruzzese E, Cantonetti M, Morino L, Orlandi G, Tendas A, Del Principe MI et al. CNS and cutaneous involvement in patients with chronic myeloid leukemia treated with imatinib in hematologic complete remission: two case reports. J Clin Oncol 2003 21 : 4256 8.
21. Leis JF, Stepan DE, Curtin PT, Ford JM, Peng B, Schubach S et al. Central nervous system failure in patients with chronic myelogenous leukemia lymphoid blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia treated with imatinib (STI-571). Leuk Lymphoma 2004 45 : 695 8.
22. Bujassoum S, Rifkind J, Lipton JH. Isolated central nervous system relapse in lymphoid blast crisis chronic myeloid leukemia and acute lymphoblastic leukemia in patients on imatinib therapy. Leuk Lymphoma 2004 45 : 401 3.
23. Bornhauser M, Jenke A, Freiberg-Richter J, Radke J, Schuler US, Mohr B et al. CNS blast crisis of chronic myelogenous leukemia in a patient with a major cytogenetic response in bone marrow associated with low levels of imatinib mesylate and its N-desmethylated metabolite in cerebral spinal fluid. Ann Hematol 2004 83 : 401 2.
24. Rajappa S, Uppin SG, Raghunadharao D, Rao IS, Surath A. Isolated central nervous system blast crisis in chronic myeloid leukaemia. Hematol Oncol 2004 22 : 179 81.
25. Rytting ME, Wierda WG. Central nervous system relapse in two patients with chronic myelogenous leukemia in myeloid blastic phase on imatinib mesylate therapy. Leuk Lymphoma 2004 45 : 1623 6.
26. Matsuda M, Morita Y, Shimada T, Miyatake J, Hirase C, Tanaka M et al. Extramedullary blast crisis derived from 2 different clones in the central nervous system and neck during complete cytogenetic remission of chronic myelogenous leukemia treated with imatinib mesylate. Int J Hematol 2005 81 : 307 9.
27. Pavlu J, Czepulkowski B, Kaczmarski R, Jan-Mohamed R. Early blastic transformation with CNS infiltration in a patient with chronic myeloid leukaemia treated with imatinib. Lancet Oncol 2005 6 : 128.
28. Kim HJ, Jung CW, Kim K, Ahn JS, Kim WS, Park K et al. Isolated blast crisis in CNS in a patient with chronic myelogenous leukaemia maintaining major cytogenetic response after imatinib. J Clin Oncol 2006 24 : 4028 9.
29. Wolff NC, Richardson JA, Egorin M, Ilaria RL. The CNS is a sanctuary for leukemic cells in mice receiving imatinib mesylate for Bcr/Abl-induced leukemia. Blood 2003 101 : 5010 3.
30. Dai H, Marbach P, Lemaire M, Hayes M, Elmquist WF. Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux. J Pharmacol Exp Ther 2003 304 : 1085 92.
31. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004 305 : 399 401.
32. Hochhaus A, Kantarjian HM, Baccarani M, Lipton JH, Apperley JF, Druker BJ et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 2007 109 : 2303 9.
33. Hochhaus A, Reiter A, Skladny H, Reichert A, Saussele S, Hehlmann R. Molecular monitoring of residual disease in chronic myelogenous leukemia patients after therapy. Recent Results Cancer Res 1998 144 : 36 45.
34. Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia 2003 17 : 2318 57.
35. Wild R, Castaneda S, Flefleh C, Fager K, Inigo I, Kan D et al. BMS-354825, a dual SRC/ABL kinase inhibitor, displays potent anti-tumor activity in a model of intracranial CML growth. Blood 2004 104 : 549a.
36. Kim S, Khatibi S, Howell SB, McCully C, Balis FM, Poplack DG. Prolongation of drug exposure in cerebrospinal fluid by encapsulation into DepoFoam. Cancer Res 1993 53 : 1596 8.
37. Glantz MJ, Jaeckle KA, Chamberlain MC, Phuphanich S, Recht L, Swinnen LJ et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 1999 5 : 3394 402.
38. Bomgaars L, Geyer JR, Franklin J, Dahl G, Park J, Winick NJ et al. Phase I trial of intrathecal liposomal cytarabine in children with neoplastic meningitis. J Clin Oncol 2004 22 : 3916 21.
39. Jabbour E, O'Brien S, Kantarjian H, Garcia-Manero G, Ferrajoli A, Ravandi F et al. Neurological complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood 2007 109 : 3214 8.